製薬 大リストラ(週刊東洋経済ｅビジネス新書Ｎo.369)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
1 credit a month to buy any audiobook in our entire collection.
Access to thousands of additional audiobooks and Originals from the Plus Catalogue.
Member-only deals & discounts.
Auto-renews at $16.45/mo after 30 days. Cancel anytime.
製薬 大リストラ(週刊東洋経済ｅビジネス新書Ｎo.369)
Narrated by:
海老塚 久蔵
Buy Now for $19.99
No valid payment method on file.
We are sorry. We are not allowed to sell this product with the selected payment method
Pay using voucher balance (if applicable) then card ending in
By confirming your purchase, you agree to Audible's Conditions Of Use and Privacy Notice and authorise Audible to charge your designated credit card or another available credit card on file.
-
Narrated by:
-
海老塚 久蔵
-
By:
-
週刊東洋経済編集部
About this listen
本タイトルには付属資料・PDFが用意されています。ご購入後、デスクトップのライブラリー、またはアプリ上の「目次」でご確認ください。（アプリバージョン：Android 2.40以上、iOS 3.11以上）
経営環境が厳しい製薬業界では、薬価の引き下げや後発品の台頭、大型新薬の開発難などがあっても、製薬は研究開発費を確保することが生き残るための必須条件だ。そこで、効率化の白羽の矢が立つのは営業体制だ。コロナ禍で対面営業が激変、「ＭＲ君」などＩＴ化の急拡大で、構造変化の影響を大きく受けるのはＭＲ（医薬情報担当者）だ。だが人員リストラだけで解決できるのか。風雲急を告げているＭＲの将来、製薬会社の苦闘を検証する。
本誌は『週刊東洋経済』２０２０年１２月１９日号掲載の２８ページ分を電子化したものです。情報は底本編集当時のものです。
©東洋経済新報社 (P)2022 Audible, Inc.What listeners say about 製薬 大リストラ(週刊東洋経済ｅビジネス新書Ｎo.369)
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.